|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF-21-transgenic mice were viable and resistant to diet-induced obesity.
|
15902306 |
2005 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum FGF21 levels in overweight/obese subjects were significantly higher than in lean individuals.
|
18252893 |
2008 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, very recent results from different human cohort studies have shown a paradoxical regulation of plasma FGF21 in obesity and type 2 diabetes as well as other important qualitative differences in the effects and regulation of FGF21 between rodents and humans.
|
19277467 |
2009 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
VLCD significantly increased FGF21 mRNA expression in subcutaneous fat of obesity.
|
19702724 |
2009 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results presented here offer a mechanism explaining the induction of the metabolic regulator FGF-21 in the fasting situation but also in type 2 diabetes and obesity.
|
19401423 |
2009 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.
|
20451522 |
2010 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
To test the hypothesis that obesity is a state of FGF21 resistance, we evaluated the response of obese mice to exogenous FGF21 administration.
|
20682689 |
2010 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical use of recombinant fibroblast growth factor 21 (FGF21) for the treatment of type 2 diabetes and other disorders linked to obesity has been proposed; however, its clinical development has been challenging owing to its poor pharmacokinetics.
|
22174314 |
2011 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that betaKlotho (KLB) and endocrine FGF19 and FGF21 redirect FGFR signaling to regulation of metabolic homeostasis and suppression of obesity and diabetes.
|
22442730 |
2012 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The unexpected finding of an antibody that can activate FGF21-like signaling through cell surface receptors provided preclinical validation for an innovative therapeutic approach to diabetes and obesity.
|
23197570 |
2012 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
|
22067317 |
2012 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation of the 3' UTR of the FGF-21 gene was associated with obesity, however, not with MetS or diabetes.
|
21988350 |
2012 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
A cytokine involved in cellular metabolism, FGF21 is a potential susceptibility gene for obesity and type 2 diabetes.
|
23372041 |
2013 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recent results suggest that FGF21 is highly expressed in hepatocytes under metabolic stress caused by starvation, hepatosteatosis, obesity and diabetes.
|
23590285 |
2013 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 21 (FGF21) has potent effects on normalizing glucose, lipid, and energy homeostasis, and represents an attractive novel therapy for type 2 diabetes mellitus and obesity.
|
23456652 |
2013 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, in human studies, high circulating FGF21 levels are found in obesity and its related cardiometabolic disorders including the metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease and coronary artery disease.
|
23134073 |
2013 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings suggest that systemic administration of liraglutide induces hepatic Fgf21 production and suppresses the social isolation-induced obesity and diabetes independently of insulin, glucagon, and active GLP-1 in KKA(y) mice.
|
24804243 |
2014 |
|
Obesity
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Strategies to activate SIRT1 or FGF21 could be used to treat fatty liver disease and obesity.
|
24184811 |
2014 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cardiac FGF21 was expressed and secreted (real time RT-PCR/western blot and ELISA) in an autocrine-paracrine manner, in response to obesity and hypoxia, involving FGFR1-βKlotho components.
|
24498293 |
2014 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although increased circulating levels of FGF21 have been documented in animal models and human subjects with obesity and nonalcoholic fatty liver disease, the functional interconnections between metabolic ER stress and FGF21 are incompletely understood.
|
25170079 |
2014 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The in vivo importance of FGF21 induction by ER stress and obesity was determined using inducible Fgf21-transgenic mice and Fgf21-null mice with or without leptin deficiency.
|
25537833 |
2015 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent microRNA (miR) studies have revealed that aberrantly elevated miR-34a in obesity directly targets β-Klotho, the obligate coreceptor for both FGF19 and FGF21, and attenuates metabolic signaling of these hormones.
|
27125742 |
2016 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A low-calorie, high-carbohydrate/low-fat diet was beneficial for overweight or obese individuals carrying the carbohydrate intake-decreasing allele of the FGF21 variant to improve body composition and abdominal obesity.
|
27581055 |
2016 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
In mice, fusion of FGF21 to PsTag prolonged and potentiated pharmacological effects of native FGF21, and may offer greater therapeutic effects in treatment of obesity.
|
27339749 |
2016 |
|
Obesity
|
0.400 |
Therapeutic
|
disease |
CTD_human |
On the basis of our findings, we propose selective FAP inhibition as a potential therapeutic approach to increase endogenous FGF21 activity for the treatment of obesity, type 2 diabetes, non-alcoholic steatohepatitis, and related metabolic disorders.
|
26797127 |
2016 |